Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697173 | 0.93 | SMN1; SMN2 (0.40) | PDE4BPDE4DTRPV4HRH3KCNH2 | |
| SCHEMBL14697302 | 0.85 | TRPV4 (0.39) | TRPV4HRH3KCNH2PIK3CGPIK3CD | |
| SCHEMBL14697276 | 0.84 | GRM1 (0.52) | PDE4BPDE4DGRM1 | |
| SCHEMBL16021382 | 0.82 | TRPV4 (0.39) | TRPV4HRH3KCNH2PIK3CGPIK3CD | |
| SCHEMBL14697124 | 0.81 | PIK3CG (0.44) | PDE4BPDE4DTRPV4HRH3KCNH2 | |
| SCHEMBL14697392 | 0.73 | LMNA (0.49) | IDO1TDO2 | |
| SCHEMBL14697079 | 0.71 | L3MBTL1 (0.49) | PDE4BPDE4DIDO1TDO2 | |
| SCHEMBL14697075 | 0.71 | SMN1; SMN2 (0.56) | IDO1TDO2 | |
| SCHEMBL28924734 | 0.70 | HRH3 (0.57) | TRPV4HRH3KCNH2PARP1 | |
| SCHEMBL14697359 | 0.69 | L3MBTL1 (0.47) | PDE4BPDE4DIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611733-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE | 2017-05-25 | — | — | US | disclosed |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE | 2017-05-25 | — | — | US | disclosed |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE | 2017-05-25 | — | — | US | disclosed |
| US-9598402-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598402-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598402-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2744787-B1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RES INST (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2744787-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | Southern Research Institute (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013025508-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | HAVCR2, EIF2AK2, GLS2 | PDE4B 1675/4885PDE4D 2671/4885GRM1 522/4885 |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | ZC3HAV1, EIF2AK2, GTF3C3 | PDE4B 1391/4885PDE4D 2123/4885GRM1 869/4885 |
| US-10611733-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | ZC3HAV1, EIF2AK2, GTF3C3 | PDE4B 1391/4885PDE4D 2123/4885GRM1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.